Pioglitazone (a synthetic ligand of PPARγ) which is used clinically for the treatment of type 2 diabetes mellitus (T2DM) mitigates steatosis, inflammation, and fibrosis in subjects with NASH (Belfort et al., 2006; Aithal et al., 2008); however, it increases the patient’s weight and risk of bladder cancer (Sanyal et al., 2010; Tang et al., 2018). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.